No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 11.1x · 10Y median 69.4x · 11th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 22
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T15:47:40.269Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Orchestra BioMed Holdings, Inc. (OBIO) stock was $5.91 as of Oct 6, 2026, 11:44 AM EDT, down 1.99% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +121.7% · 3-year avg -7.7%/yr · 5-year avg -9.3%/yr
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector.
Biotechnology · New Hope, PA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 9, 2026
34 days away
EPS Estimate
-0.40
Revenue Est.
$129429.00
Last Quarter Results
EPS
$-0.38
vs Estimate
$-0.39
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1OBIO | $353.90M | $5.91 | -1.99% | +121.66% | -9.35% | N/A | N/A |
| 2ARTV | $354.45M | $7.25 | +1.68% | +140.68% | N/A | N/A | vs OBIO |
| 3ENTA | $356.17M | $12.25 | -2.79% | +21.86% | -26.94% | -7.11% | vs OBIO |
| 4EMBC | $356.26M | $6.00 | +2.13% | -57.42% | N/A | N/A | vs OBIO |
| 5FENC | $356.56M | $10.26 | -3.35% | +7.45% | +2.45% | N/A | vs OBIO |
| 6OCGN | $359.46M | $1.06 | +1.92% | -41.09% | -31.57% | -40.73% | vs OBIO |
forward FY estimate
N/A
$88000.00
vs Estimate
$137714.00
Consensus Rating
Based on 7 analysts
Average Price Target
$12.43
+110.3% upside
Low
$9.00
Current
$5.91
High
$20.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.45 | $-0.40 | $-0.37 | 5 |
| Quarter ending Dec 2026 | $-0.48 | $-0.41 | $-0.37 | 5 |
| Quarter ending Mar 2027 | $-0.59 | $-0.38 | $-0.28 | 3 |
| Quarter ending Jun 2027 | $-0.57 | $-0.37 | $-0.27 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.64 | $-1.52 | $-1.45 | 5 |
| FY 2027 | $-1.69 | $-1.51 | $-1.37 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $105895.00 | $129428.00 | $164726.00 | 4 |
| Quarter ending Dec 2026 | $100821.00 | $134429.00 | $179238.00 | 4 |
| Quarter ending Mar 2027 | $76656.00 | $96600.00 | $136704.00 | 2 |
| Quarter ending Jun 2027 | $88877.00 | $112000.00 | $158497.00 | 2 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $408435.00 | $451429.00 | $537415.00 | 6 |
| FY 2027 | $293535.00 | $577286.00 | $1.25M | 6 |
